I n response to pathological stimuli such as prolonged mechanical stress, massive tissue injury, or abnormal neurohumoral activation, hearts show hypertrophic growth and remodeling, which is characterized by an increase in myocyte cell size, assembly of sarcomere proteins, interstitial fibrosis, and reexpression of fetal cardiac genes. Although the hypertrophic response is initially compensatory, it ultimately causes heart failure, which is now a leading cause of morbidity and mortality around the world. Diverse intracellular signaling pathways exerting pro-or antihypertrophic effects have been shown to play important roles in the complex processes of cardiac remodeling, 1,2 but the details of the molecular mechanisms mediating the crosstalk among these signaling pathways remain uncertain. Unraveling those details should give us a better understanding of the molecular processes underlying the establishment of cardiac hypertro-phy and heart failure, which could ultimately lead to the discovery of novel therapeutic targets for prevention of pathological cardiac remodeling.
The heart regulates cardiovascular homeostasis in part by secreting 2 peptide mediators, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). 3, 4 ANP and BNP bind to their common receptor, guanylyl cyclase (GC)-A (also called NPR-A and NPR1), which then catalyzes the synthesis of cGMP, leading to the activation of protein kinase (PK)G. 5, 6 Under pathological conditions in the heart, there is a significant increase in the ventricular expression of both ANP and BNP, 4, 7, 8 which then act as both endocrine and local antihypertrophic factors. 9 Indeed, ANP/BNP have been shown to exert antihypertrophic effects on cardiac myocytes in vitro and in vivo 10 -14 by counteracting multiple prohypertrophic signaling pathways, including the MEK1-ERK1/2 (mitogen-associated/ extracellular regulated kinase 1-extracellular regulated kinase 1/2) pathway, the Ca 2ϩ /calmodulin-dependent kinase II pathway, the Akt pathway, and the calcineurinnuclear factor of activated T cell (NFAT) pathway. 1, 2, [15] [16] [17] ANP/BNP reportedly antagonize prohypertrophic signaling by inhibiting receptor-mediated Ca 2ϩ influx into cells through activation of regulator of G-protein signaling (RGS) proteins and inhibition of L-type voltage-dependent Ca 2ϩ channels (LTCCs) and the Na ϩ /H ϩ exchanger. 10, [17] [18] [19] [20] Still, much of the network of molecular mediators via which ANP/BNP inhibit cardiac hypertrophy remains to be characterized.
The serine-threonine phosphatase calcineurin functions as a Ca 2ϩ -dependent regulator of cardiac hypertrophy and the fetal gene program. 21 Calcineurin dephosphorylates NFAT family transcription factors and induces their translocation to the nucleus, where they bind to the regulatory regions of cardiac genes in conjunction with other cardiac transcription factors and promote hypertrophic growth. 21 Transient receptor potential subfamily C (TRPC)3 and -6 reportedly serve as positive upstream regulators of the calcineurin-NFAT signaling pathway. [22] [23] [24] TRPC3 and 6 form homo-and heteromultimeric cation channels that are activated directly by diacylglycerol 25, 26 and function to couple receptor-phospholipase C activity to Ca 2ϩ influx, which in turn activates calcineurin-NFAT signaling pathways and possibly other Ca 2ϩ -dependent signaling pathways. 26 NFAT also activates TRPC6 gene transcription, thereby accelerating the calcineurin-NFAT prohypertrophic signaling loop. 23 It was recently shown that TRPC3 and 6 activities are greatly attenuated by PKG-catalyzed phosphorylation of Thr11 and Ser263 in TRPC3 and Thr69 in TRPC6, which are well conserved among mouse, rat and human. 27, 28 In the present study, we examined the functional crosstalk between the ANP/BNP-GC-A-cGMP-PKG and TRPC6-calcineurin-NFAT pathways during the process of cardiac hypertrophy and characterized its biological significance in cardiac pathophysiology. Our findings demonstrate that TRPC6 is a direct target of ANP/BNP-GC-A-cGMP-PKG antihypertrophic signaling and suggest that inhibition of TRPC6 could represent a novel therapeutic strategy for preventing pathological cardiac hypertrophy and remodeling.
Methods

Plasmid Construction
Regulator of calcineurin (RCAN)1-luciferase (RCAN1-luc), in which RCAN1 intron 3 containing 15 NFAT sites was inserted upstream of the luciferase gene, was kindly provided by B. A. Rothermel (University of Texas, Southwestern Medical Center, Dallas). 29 Expression vectors encoding wild-type (WT) and mutant (T69A) mouse TRPC6 were described previously. 28 
Cell Culture
Primary neonatal rat ventricular myocytes were isolated and grown as described previously. 30 
Patch Clamp Studies
The details of the patch clamp recording and data analysis were essentially the same as described previously. 31 
Animal Experiments
The animal care and all experimental protocols were reviewed and approved by the Animal Research Committee at Kyoto University Graduate School of Medicine. Beginning at 12 weeks of age, GC-A knockout (KO) mice (C57BL/6 background) were left untreated (control) or were treated for 4 weeks with BTP2 (20 mg/kg per day PO) or nitrendipine (40 mg/kg per day PO). BTP2 was dissolved in methylcellulose (Shin-Etsu Chemical) to a concentration of 3.0 mg/mL and was given daily via gastric gavage adjusted to the individual body weight of each mouse. The same amount of 0.5% methylcellulose was given to the other treatment groups in the same manner. Nitrendipine was given as described previously. 32 
Echocardiographic Analysis
Echocardiography was carried out as described previously 33, 34 using a Toshiba Power Vision 8000 echocardiography system equipped with a 12-MHz imaging transducer.
Statistical Analysis
Data are presented as meansϮSEM. Unpaired t tests were used for comparisons between 2 groups, and ANOVA with post hoc Fisher tests was used for comparisons among groups. Values of PϽ0.05 were considered significant.
Results
Signaling via the ANP-cGMP-PKG Pathway Inhibits Endothelin-1-Induced, TRPC6-Mediated Activation of Calcineurin-NFAT Signaling in Cardiac Myocytes
In previous reports, TRPC family ion channels (TRPC3 and TRPC6) were shown to play a central role in activating calcineurin-NFAT signaling in the ventricular myocardium during the process of pathological cardiac hypertrophy. [22] [23] [24] 35 Consistent with those reports, we found that in cultured neonatal rat ventricular myocytes, BTP2, a selective TRPC inhibitor, 36 -40 significantly and dose-dependently inhibited endothelin (ET)-1-induced activation of the NFAT-dependent RCAN1 promoter, with and without overexpression of TRPC6 ( Figure 1A ). BTP2 also significantly attenuated ET-1-induced hypertrophic responses, including increased expression of ANP, RCAN1 and TRPC6 mRNA and enlargement of cultured cardiac myocytes (Figure 1B and 1C; and Online Figure I , A through C, in the Online Data Supplement, available at http://circres.ahajournals.org). To determine whether ANP inhibits calcineurin-NFAT signaling through TRPC6 inhibition, we examined the effect of ANP on ET-1-induced, TRPC6-mediated activation of calcineurin-NFAT signaling in cultured ventricular myocytes transfected with a RCAN1 promoter-reporter gene and/or an expression vector for TRPC6. Even without overexpression of TRPC6, ET-1 induced RCAN1 promoter activity in ventricular myocytes, and this activity was significantly inhibited by ANP ( Figure 1D ). With overexpression of TRPC6, basal RCAN1 promoter activity was higher than without it, and ET-1 increased the promoter's activity still further ( Figure 1D ). ANP then significantly inhibited the ET-1-induced, TRPC6-enhanced RCAN1 promoter activity. Moreover, when cells were transfected with a TRPC6 T69A mutant, in which the PKG-phosphorylation site, Thr69, was substituted with an Ala, the basal and ET-1-induced activities of the RCAN1 promoter were comparable to those obtained with overexpression of WT TRPC6, but the inhibitory effects of ANP were almost completely abolished ( Figure 1D ). 8Br-cGMP, a membrane-permeant cGMP analogue, also significantly in- hibited ET-1-induced RCAN1 promoter activation in cardiac myocytes cotransfected with WT TRPC6 or not, but it failed to inhibit the response in myocytes cotransfected with the TRPC6 T69A mutant ( Figure 1E ). This suggests that signaling in the ANP-GC-A-cGMP-PKG pathway leads to phosphorylation of TRPC6 on Thr69, which inhibits receptormediated TRPC6 channel activation and, in turn, activation of calcineurin-NFAT signaling in cardiac myocytes. Indeed, using a specific antibody against phosphorylated Thr69, we confirmed that ANP stimulates phosphorylation of TRPC6 Thr69 in cardiac myocytes, and that the phosphorylation was blocked in the presence of the selective PKG inhibitor KT5823 ( Figure 1F ).
ANP-cGMP-PKG Signaling Inhibits TRPC6 Ion Channel Activity
We next examined the effects of ANP-cGMP-PKG signaling on TRPC6 ion channel activity. In HEK293 cells expressing WT TRPC6, the membrane-permeant diacylglycerol analogue oleoyl-2-acetyl-sn-glycerol (OAG) induced a significant increase in Ca 2ϩ influx ( Figure 2A , top left) that was dramatically inhibited by prior application of ANP ( Figure 2A , bottom left). By contrast, in HEK293 cells expressing the TRPC6 T69A mutant, OAG-induced Ca 2ϩ influx was unaffected by ANP, indicating that ANP directly inhibits OAG-induced TRPC6 channel activity through the PKG-phosphorylation site ( Figure 2A , right graphs, and 2B).
To evaluate the effect of ANP on receptor-mediated activation of TRPC6, we next stimulated HEK293 cells using ATP and examined the effect of ANP on ATP-induced TRPC6 activation. In control cells, which did not express TRPC6, ATP did not induce sustained Ca 2ϩ influx, and ANP had no effect ( Figure 2C ). In cells expressing WT TRPC6, by contrast, ATP induced sustained Ca 2ϩ influx, which was significantly inhibited by ANP ( Figure 2D ). Moreover, mutation of the PKG-phosphorylation site (T69A) in TRPC6 abolished the ANP-induced inhibition of ATP-evoked Ca 2ϩ influx ( Figure 2E ). This means that ANP acts in a PKGdependent manner to inhibit TRPC6 activation via Gqcoupled receptors. RGS2 and RGS4 are reportedly involved in the cGMP-mediated inhibition of Gq-coupled receptor signaling pathways, including the calcineurin-NFAT pathway. 20 tion of Gq upstream of TRPC6, we assessed the endogenous expression of RGS2 and RGS4 in HEK293 cells and confirmed expression of both RGS2 and RGS4 mRNA (Online Figure I, D) . Thus our finding that ATP-induced activation of the PKG-resistant TRPC6 T69A mutant in the presence of ANP was similar to seen with WT TRPC6 in the absence of ANP, despite endogenous expression of RGS2 and 4, indicates the existence of an RGS2/4-independent pathway via which ANP inhibits Gq-mediated TRPC6 activation ( Figure 2D and 2E) .
We also measured cationic currents induced by carbachol in HEK293 cells expressing TRPC6 ( Figure 2F ) and found that they were significantly inhibited in the presence of ANP ( Figure 2F and 2G) . Furthermore, the inhibitory effect of ANP was substantially blunted in cells expressing the TRPC6 T69A mutant, again confirming that ANP inhibits Gqcoupled receptor-mediated TRPC6 activation directly through the PKG-phosphorylation site ( Figure 2G ). Likewise cationic currents carried by TRPC6 channels activated by GTP␥s were also inhibited by ANP (Online Figure I , E), and this inhibitory effect was significantly blunted in the presence of DT-3, a selective PKG I␣ inhibitor, or by mutation (T69A) of TRPC6 (Online Figure I, F) . All of these data indicate that signaling via the ANP-cGMP-PKG pathway inhibits TRPC6 ion channel activity through direct phosphorylation of TRPC6.
ANP Inhibits Agonist-Induced Ca 2؉ Influx Into Ventricular Myocytes
We next examined the inhibitory effect of ANP on Ca 2ϩ signaling in cardiac myocytes. When we used Fura-2 to measure the frequency of Ca 2ϩ oscillations induced by ET-1 or angiotensin II (Ang II) in cultured neonatal ventricular myocytes, we found that both increased the frequency of Ca 2ϩ oscillation in the cells, that this effect was significantly inhibited by ANP ( Figure 3A and 3B) , and that the inhibitory effect of ANP was almost completely abolished in the presence of KT5823 ( Figure 3C and 3D). ET-1-or Ang II-induced increases in Ca 2ϩ oscillation were also significantly inhibited when TRPC3 and 6 were simultaneously knocked down using small interfering (si)RNAs ( Figure 3E and 3F, and Online Figure  II , A, D, F, and I). 24 Moreover, knocking down either TRPC3 or 6 had a similar effect (Online Figure II, A, B , C, E, F, G, H, and J). This suggests that TRPC3 and 6 act in concert to mediate ANP-sensitive, ET-1-or Ang IIinduced increases in Ca 2ϩ oscillation in cardiac myocytes. ET-1 and Ang II also induced Ca 2ϩ influx into cardiac myocytes that was significantly inhibited by ANP ( Figure  4A and 4B). We previously showed that knocking down either TRPC3 or 6 significantly reduced Ang II-induced Ca 2ϩ influx into cardiac myocytes. 24 In the present study, we found that knocking down TRPC3 and 6 significantly inhibited ET-1-and Ang II-induced Ca 2ϩ influx and abolished the inhibitory effect exerted by ANP on this Ca 2ϩ influx, which suggests ANP inhibits TRPC3/6-mediated Ca 2ϩ influx into cardiac myocytes (Figure 4C  and 4D ; Online Figure III, A through D) .
To further determine whether TRPC channels or LTCCs were responsible for the ANP-induced inhibition of agonist-induced Ca 2ϩ influx in cultured ventricular myocytes, we tested the effects of nitrendipine, a selective LTCC inhibitor, and BTP2 on the Ca 2ϩ influx. Although nitrendipine reduced the overall Ca 2ϩ influx induced by ET-1 or Ang II, the inhibitory effect of ANP was preserved ( Figure 5A and 5B). By contrast, ANP-induced inhibition of agonist-evoked Ca 2ϩ influx was almost completely blocked in the presence of BTP2 ( Figure 5C ). The dose of BTP2 we used in this study did not affect KCl-induced, nitrendipine-sensitive Ca 2ϩ influx ( Figure 5D ). These findings further confirm that inhibition of TRPCs, not LTCCs, is a critical component of the inhibitory effect of ANP on ET-1 and Ang II-induced Ca 2ϩ influx into cultured ventricular myocytes.
We also assessed the contribution made by RGS2 and RGS4 to ANP-induced inhibition of Gq-coupled receptormediated Ca 2ϩ influx into cardiac myocytes by using siRNAs to simultaneously knock down their expression. We initially confirmed that the RGS2 and RGS4 siRNAs efficiently and specifically knocked down RGS2 and RGS4 mRNA levels to 18% and 27%, respectively, of those seen with control siRNA in ventricular myocytes ( Figure 5E ). In ventricular myocytes cotransfected with RGS2 and RGS4 siRNAs, ANP still significantly inhibited ET-1-and Ang II-induced Ca 2ϩ influx, but this inhibitory effect was significantly attenuated (Figure 5F and 5G; Online Figure IV, A and B) . In addition, type1a Ang II receptor densities and the expression levels of mRNAs and proteins related to Gq-coupled receptormediated Ca 2ϩ influx were not significantly altered (Online Figure IV, C through E). Collectively then, these results support our notion that ANP inhibits ET-1-and Ang IIinduced Ca 2ϩ influx into cardiac myocytes in a manner that is, at least in part, TRPC-dependent.
TRPC Channels Play a Pivotal Role in Cardiac Hypertrophy in GC-A KO Mice
ANP increases intracellular cGMP via its receptor, GC-A, a particulate type of guanylyl cyclase. GC-A KO mice, which lack GC-A, exhibit reduced plasma cGMP levels, salt-resistant hypertension and cardiac hypertrophy. [43] [44] [45] Activation of calcineurin-NFAT signaling is reportedly involved in the development of the cardiac hypertrophy seen in GC-A KO mice, 2, 15 and because TRPC6 forms a positive regulatory circuit with the calcineurin-NFAT pathway, 23 we examined whether TRPC6 gene expression is induced in the ventricles of GC-A KO mice. Real-time RT-PCR analysis clearly showed a significant increase in the expression of TRPC6, ANP, BNP and TRPC3 mRNA in GC-A KO ventricles ( Figure 6A ), which is consistent with the notion that GC-A negatively regulates calcineurin-NFAT prohypertrophic signaling. The levels of TRPC3 and 6 protein were also significantly higher in GC-A KO ventricles than WT ventricles (Online Figure V,  A and B) . To evaluate the contribution made by TRPC6 and 3 to the development of cardiac hypertrophy, we treated GC-A KO mice with BTP2. Although BTP2 did not affect blood pressure or heart rate in GC-A KO mice ( Figure 6B ), it significantly reduced cardiac hypertrophy assessed based on heart weight (HW), heart weight/body weight (HW/BW) ratios, and myocardial cell diameters measured in histological samples ( Figure 6C and 6D) . By contrast, nitrendipine did not reduce cardiac hypertrophy in GC-A KO mice, though it modestly reduced blood pressures (WT without nitrendipine, 94.5Ϯ0.5 mm Hg; WT with nitrendipine, 89.7Ϯ3 mm Hg; GC-A KO without nitrendipine, 119.8Ϯ2.1 mm Hg; GC-A KO with nitrendipine, 116.2Ϯ1.5 mm Hg; Online Figure V, C through E; Online Table I ). BTP2 also reduced cardiac fibrosis in GC-A KO mice ( Figure 6E ). Consistent with these findings, echocardiographic analysis showed that BTP2 reduced posterior wall thickness and restored left ventricular end-diastolic dimension in GC-A KO ventricles without affecting % fractional shortening ( Figure 6F ). In addition, the increased ventricular expression of RCAN1 and such hypertrophy marker genes as ANP, BNP, ␤-myosin heavy chain (␤MHC), and skeletal ␣-actin in GC-A KO ventricles was dramatically attenuated by BTP-2 ( Figure 7A ), though expression of ␣-myosin heavy chain (␣MHC) and cardiac ␣-actin was not ( Figure 7A) . Likewise, the increased expression of TRPC6 and TRPC3 seen in GC-A KO ventricles was diminished by BTP2 treatment ( Figure 7A ). Clearly, TRPC-mediated signaling is significantly involved in the development of pathological cardiac hypertrophy induced by a genetic deletion of GC-A.
Exaggerated Cardiac Hypertrophy in Mice With Cardiac Overexpression of TRPC6 Against a GC-A-Null Background
To further confirm the negative functional interaction of the ANP-GC-A-cGMP-PKG and TRPC6-calcineurin-NFAT pathways, we next crossed transgenic mice cardioselectively expressing TRPC6 (TRPC6 Tg; previously referred to as line 16) with GC-A KO mice. 23 As previously reported, 12-week-old TRPC6 Tg mice did not show cardiac hypertrophy, as compared to WT mice, whereas GC-A KO mice showed a significant increase in blood pressure, HW and HW/BW ratios ( Figure 7B and 7C) . 23, 44 Moreover, TRPC6 Tg mice with a GC-A-null background showed significantly greater HW/BW ratios than GC-A KO mice, without an increase in blood pressure, which is indicative of the hypersensitivity of GC-A KO mice to TRPC6-mediated prohypertrophic signaling ( Figure 7B and 7C). Consistent with this finding, echocardiographic analysis showed ventricular wall thicknesses to be greater in GC-A; TRPC6 Tg mice than GC-A KO mice, without a change in systolic function ( Figure 7D ).
TRPC Inhibition Prevents Ang II-Induced Cardiac Hypertrophy
The notion that TRPC6 inhibition is a critical component of the antihypertrophic effects exerted via the ANP-GC-A-cGMP-PKG pathway suggests that direct inhibition of TRPC6 could be a novel therapeutic approach to preventing pathological cardiac hypertrophy. Indeed, BTP2 significantly inhibited the cardiac hypertrophy otherwise seen in GC-A KO mice ( Figure 6C through 6F and Figure 7A ). To further test this hypothesis using models of cardiac hypertrophy in which GC-A-cGMP-PKG signaling is genetically intact, we examined the effects of BTP2 on Ang II-induced cardiac hypertrophy. When we chronically infused Ang II using a subcutaneously implanted osmotic minipump, we observed a significant increase in blood pressure and HW/BW ratios ( Figure 8A and 8B). Administration of BTP2 significantly inhibited Ang II-induced cardiac hypertrophy assessed based on HW/BW ratios, without affecting blood pressure ( Figure 8A and 8B). Echocardiographic analysis confirmed that BTP2 inhibited the Ang II-induced hypertrophic response in the heart ( Figure 8C and Online Table II) , without affecting systolic function (Online Table II ). In addition, the increase in the cardiac expression of the hypertrophy marker genes RCAN1, BNP, ␤MHC, and skeletal ␣-actin, which was observed in Ang II-treated mice, was significantly inhibited by BTP2 treatment ( Figure 8D ), whereas expression of cardiac ␣-actin, TRPC6, and TRPC3 was not significantly affected in mice treated with or without Ang II and/or BTP2 ( Figure 8D ; Online Figure V, F and G).
Discussion
Characterization of the crosstalk among the cardiac signaling pathways that promote or antagonize hypertrophic responses should lead to a better understanding of molecular processes underlying the establishment of cardiac hypertrophy and heart failure, which could ultimately lead to the discovery of novel therapeutic approaches to preventing pathological cardiac remodeling. In the present study we unraveled the functionally negative crosstalk between the ANP-GC-AcGMP-PKG and TRPC6-calcineurin-NFAT pathways in cardiac myocytes using in vitro culture systems and in vivo genetically engineered models. ANP acted via the cGMP-PKG pathway to directly inhibit TRPC6 activity, which in turn suppressed prohypertrophic signaling. Cardiac hypertrophy was significantly attenuated by the selective TRPC inhibitor BTP2 in GC-A KO mice, which were hypersensitive to hypertrophic signaling caused by overexpression of TRPC6. Likewise, BTP-2 significantly inhibited the cardiac hypertrophy induced by chronic Ang II infusion. Our study thus demonstrates that inhibition of TRPC6 activity mediates the antihypertrophic effects of ANP/BNP, and suggests that inhibition of TRPC6 could be an effective therapeutic strategy for preventing pathological cardiac hypertrophy and remodeling. It was recently reported that RGS4 mediates the antihypertrophic effects of GC-A-catalyzed signaling in the heart. 20 RGS2 also reportedly mediates the antihypertrophic effects of inhibiting phosphodiesterase 5, which enhances activity in the NO-cGMP pathway. 41 It is thus suggested that RGS proteins mediate the antihypertrophic effects exerted by cGMP. In our study, we confirmed that RGS2 and 4 are significantly involved in the ANP-induced inhibition of agonist-induced Ca 2ϩ influx ( Figure 5G ). PKG-catalyzed phosphorylation of TRPC6 on Thr69 is significantly involved in ANP-induced inhibition of receptor-mediated TRPC6 activity, despite the expression of RGS2 and RGS4 mRNA in HEK293 cells, however ( Figure 2D , 2E, and 2G; Online Figure I, D) . Agonist-induced activation of the TRPC6 T69A mutant in the presence of ANP was around 80% to 90% of that seen with WT TRPC6 in the absence of ANP. Furthermore, even when we knocked down both RGS2 and RGS4, the significant inhibitory effect of ANP on agonist-induced Ca 2ϩ influx was preserved in cardiac myocytes (Figure 5E through 5G; Online Figure IV, A and B) . Thus, RGS-independent mechanisms also contribute to the antihypertrophic effects of cGMPdependent signaling. This is not surprising, as multiple mechanisms would be expected to participate in the antihypertrophic effects exerted via the ANP/BNP-GC-A-cGMP-PKG pathway. In that regard, PKG also reportedly inhibits LTCC activity and calcineurin-NFAT signaling. 18 Although under our experimental conditions treatment with the LTCC blocker nifedipine did not significantly attenuate the inhibitory effect of ANP on agonist-induced Ca 2ϩ influx into cardiac myocytes, inhibition of LTCCs can contribute to the antihypertrophic effects of ANP. Indeed, activation of TRPC3/6 has been shown to lead to LTCC activation, 24 and ANP may inhibit that activation, thereby inhibiting calcineurin-NFAT signaling. It therefore seems likely that ANP/BNP-GC-A-cGMP-PKG signaling inhibits prohypertrophic signaling pathways at multiple steps. ANP and BNP are already administered clinically to patients with acute heart failure. 46, 47 But because, currently, these drugs are only administered intravenously, they are not available for use in the treatment of chronic pathological conditions such as cardiac hypertrophy and chronic heart failure. Development of nonpeptide GC-A agonists that can be administered orally may lead to the development of new therapeutic agents for preventing pathological cardiac hypertrophy and remodeling.
It has been shown in separate studies that GC-A is desensitized in failing human hearts 48 and that Ang II and ET-1 act to desensitize GC-A. 49 This makes it unlikely that under pathological conditions, endogenous cardiac ANP/ BNP-GC-A-cGMP signaling would be sufficient to block the pathological signaling activity. Such disruption of the balance between anti-and prohypertrophic signaling would lead to further activation of TRPC3/6-dependent prohypertrophic signaling, thereby promoting the pathological cardiac remodeling. Thus inhibition of TRPC3/6 channel activity could be an effective therapeutic strategy for preventing cardiac remodeling under these pathological conditions. Indeed, our finding that BTP2 attenuated cardiac hypertrophy in GC-A KO and Ang II-infused mice may support this notion. In that regard, Pyr3 is a pyrazole compound recently identified as a specific inhibitor for TRPC3 that blocks Ca 2ϩ influx carried by TRPC3/6 heteromeric complexes and by TRPC3 homomeric complexes. Moreover, Pyr3 also inhibited Ang II-induced hypertrophic responses in cultured cardiac myocytes more potently than BTP2. 37 In our study, knocking down either TRPC3 or -6 in cardiac myocytes significantly inhibited ET-1-and Ang II-induced increases in Ca 2ϩ oscillation to levels comparable to those seen when both TRPC3 and -6 were knocked down simultaneously (Online Figure II, A through J). This raises the possibility that a TRPC3/6 heteromeric complex plays a key role in mediating agonistinduced prohypertrophic signaling in cardiac myocytes. Development of highly specific TRPC6 inhibitors could lead to the development of more potent and safer agents with which to prevent pathological cardiac remodeling and heart failure. 
